Stocks Health care ACRV
NASDAQ · Health careAcrivon Therapeutics, Inc. (ACRV)
It posted a net loss of $74.2M. In fiscal 2025 capital spending exceeded operating cash flow by $65.3M. At June 30, 2026 it held $41.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Acrivon Therapeutics, Inc.
- Net worth
- Acrivon Therapeutics, Inc. has a market value (market cap) of $67.7M at the latest share price, and shareholders' equity of $86.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $63.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Acrivon Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Acrivon Therapeutics, Inc. does
Acrivon Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACRV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$77.9M | -$2.02 | -$65.3M |
| 2024 | n/a | -$80.6M | -$2.38 | -$68.4M |
| 2023 | n/a | -$60.4M | -$2.74 | -$43.9M |
| 2022 | n/a | -$31.2M | -$7.56 | -$32.3M |
| 2022 | n/a | -$16.2M | -$9.32 | -$14.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Acrivon Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 12, 2026
- August 12, 2026
- June 17, 2026
- May 22, 2026Additional proxy material DEFA14A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026
- May 13, 2026
- April 30, 2026
Insider trades
What the people running Acrivon Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $37K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 31, 2026 | Levin MichaelaChief Business Officer | Received as pay | 30,000 | - |
| August 25, 2026 | Blume-Jensen PeterPresident and CEO, Director | Sold | 14,036 | $31K |
| August 18, 2026 | Blume-Jensen PeterPresident and CEO, Director | Sold | 1,229 | $2.5K |
| August 18, 2026 | Blume-Jensen PeterPresident and CEO, Director | Soldindirect | 484 | $972.8 |
| August 18, 2026 | Devroe EricChief Operating Officer | Sold | 604 | $1.2K |
| August 18, 2026 | Gamelin ErickChief Development Officer | Sold | 400 | $804 |
| August 18, 2026 | Miller MaryChief Legal Officer | Sold | 185 | $371.8 |
| August 18, 2026 | Peterson KatharineChief Accounting Officer | Sold | 101 | $203 |
Who owns ACRV
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13D, may seek influence with 3 related filers | 28.8% | April 23, 2026 |
| Sands Capital Life Sciences Pulse Fund II, L.P.13G, passive with 2 related filers | 5.3% | August 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 46 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 12,229,396 | +3,888,888 |
| Sands Capital Alternatives, LLC | 2,289,271 | +166,666 |
| Vanguard Capital Management LLC | 952,008 | +229,973 |
| Wellington Management Group Llp | 888,130 | 0 |
| Renaissance Technologies LLC | 758,863 | +423 |
| Two Sigma Investments, LP | 641,498 | +252,103 |
| Marshall Wace, Llp | 531,856 | -28,580 |
| Bridgeway Capital Management, LLC | 378,900 | +220,000 |
| Geode Capital Management, LLC | 265,241 | +28,850 |
| BlackRock, Inc. | 239,112 | +30,173 |
| Vanguard Fiduciary Trust Co | 184,128 | +76,599 |
| XTX Topco Ltd | 178,239 | +111,357 |
| Jane Street Group, LLC | 74,648 | -165,043 |
| Northern Trust Corp | 67,202 | +18,300 |
| State Street Corp | 67,145 | 0 |
| UBS Group AG | 43,850 | +9,216 |
| Citadel Advisors LLC | 41,276 | new |
| Dimensional Fund Advisors LP | 29,332 | +10,968 |
| Spark Investment Management LLC | 28,300 | new |
| Prelude Capital Management, LLC | 24,015 | 0 |
Insiders
15 insiders reported holding 3,115,281 shares in total, about $4.9M at the last price.
| Holder | Shares |
|---|---|
| Blume-Jensen PeterPresident and CEO, Director | 2,615,911385,859 held indirectly |
| Devroe EricChief Operating Officer | 146,349 |
| Miller MaryChief Legal Officer | 82,009 |
| Levy Adam D.Chief Financial Officer | 66,008 |
| Gamelin ErickChief Development Officer | 52,592 |
| Mirza Mansoor RazaChief Medical Officer | 38,817 |
| Levin MichaelaChief Business Officer | 30,000 |
| Peterson KatharineChief Accounting Officer | 18,033 |
| Shacham SharonDirector | 9,366 |
| Baum Charles MDirector | 9,366 |
Questions about ACRV
What does Acrivon Therapeutics, Inc. do?
Acrivon Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ACRV. Its shares trade on NASDAQ under the ticker ACRV.
What is Acrivon Therapeutics, Inc.'s net worth?
Acrivon Therapeutics, Inc. has a market value (market cap) of $67.7M at the latest share price, and shareholders' equity of $86.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Acrivon Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $74.2M.
When did Acrivon Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 2, 2026.
When is Acrivon Therapeutics, Inc.'s next earnings report?
Acrivon Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ACRV with
Follow ACRV
Get an email when Acrivon Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Acrivon Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.